ARCHIVES

New Treatment For CML Could Be Model for Molecular Target-Based Therapeutics

This article is from The Cancer Letter archive.

Vol. 25 No. 47 | December 10, 1999

Download PDF Visit The Full Archive

Related Articles

RFAs available: Chemoprevention Clinical Trials

July 22, 1994

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

In Brief: Interim Dean Henney Looking for Cancer Center Director; Shingleton Gets James Ewing Award

June 10, 1988

Ten Cooperative Group Chairs Propose Eight “Guiding Principles” For Change

May 20, 2011

Drugs Available To Investigators Centers to Monitor Them Are Listed

September 9, 1977

State Cancer Incidence Report Published by NCI, CDC

November 22, 2002